|
|
||||||||
Eur J Cardiothorac Surg 2006;29:479-485
© 2006 Elsevier Science NL
Review |
a Research Group Experimental Surgery, Department of Thoracic- and Cardiovascular Surgery, University Hospital Duesseldorf, Moorenstr. 5, D-40225 Düsseldorf, Germany
b Department of Thoracic- and Cardiovascular Surgery, University Hospital Duesseldorf, Duesseldorf, Germany
Received 10 November 2005; received in revised form 11 January 2006; accepted 12 January 2006.
* Corresponding author. Tel.: +49 211 81 19949; fax: +49 211 81 16996. (Email: schipke{at}med.uni-duesseldorf.de).
Glucoseinsulinpotassium (GIK) solutions have been used in cardiac surgery for more than 40 years. At that time, membrane-polarizing and stabilizing effects on cardiomyocyte's action potential were regarded the main benefit. Two meta-analyses described methodological flaws in the early studies (e.g., case numbers, randomization principles, and levels of significance), and came to clearly different recommendations with regard to the usage of GIK in the therapy of acute myocardial function. During the 70s, as promising therapies for the treatment of AMI had become available (e.g., ß-blockers and thrombolytic agents), the GIK technique was more widely introduced in cardiac surgery, e.g., during valve replacement. At present, 74 of 91 studies provide convincing evidence for the beneficial effects of insulin and/or GIK in cardiac surgery that go far beyond simple metabolic benefits and also include better recovery of myocardial tissue after ischemia. Yet, the exact underlying mechanisms remain still unknown. In this review article, two questions will be answered: why did GIK not become daily routine in cardiac surgery in spite of positive results from clinical studies, and does this technique merit more acceptance among the potential users? In view of the increasing number of older patients at higher risk, the demand for improving surgical procedures has renewed the interest in the GIK concept. The more recent literature suggests that the entire potential of GIK solutions has not been fully disclosed. A large single or multicenter trial with sound endpoints is mandatory.
Key Words: Cardioprotection GIK mechanisms Randomized trials Endpoints
This article has been cited by other articles:
![]() |
L. Bertrand, S. Horman, C. Beauloye, and J.-L. Vanoverschelde Insulin signalling in the heart Cardiovasc Res, July 15, 2008; 79(2): 238 - 248. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Albacker, G. Carvalho, T. Schricker, and K. Lachapelle High-dose insulin therapy attenuates systemic inflammatory response in coronary artery bypass grafting patients. Ann. Thorac. Surg., July 1, 2008; 86(1): 20 - 27. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gandhi, B. A. Finegan, and A. S. Clanachan Role of glucose metabolism in the recovery of postischemic LV mechanical function: effects of insulin and other metabolic modulators Am J Physiol Heart Circ Physiol, June 1, 2008; 294(6): H2576 - H2586. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Kloner and R. W. Nesto Glucose-Insulin-Potassium for Acute Myocardial Infarction: Continuing Controversy Over Cardioprotection Circulation, May 13, 2008; 117(19): 2523 - 2533. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |